PBYI
Price
$8.36
Change
-$1.41 (-14.43%)
Updated
Nov 6, 11:59 AM (EDT)
Capitalization
504.33M
118 days until earnings call
Intraday BUY SELL Signals
RYTM
Price
$105.94
Change
+$0.92 (+0.88%)
Updated
Nov 6, 11:37 AM (EDT)
Capitalization
7.23B
117 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

PBYI vs RYTM

PBYI vs RYTM Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
PBYI vs. RYTM commentary
Nov 06, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PBYI is a Buy and RYTM is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for PBYI with price predictions
Nov 05, 2026

PBYI's RSI Indicator leaves overbought zone

The 10-day RSI Indicator for PBYI moved out of overbought territory on October 23, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 42 instances where the indicator moved out of the overbought zone. In 37 of the 42 cases the stock moved lower in the days that followed. This puts the odds of a move down at 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PBYI as a result. In 76 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.

The Moving Average Convergence Divergence Histogram (MACD) for PBYI turned negative on October 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 36 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 77%.

PBYI moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PBYI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a +5.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where PBYI advanced for three days, in 261 of 292 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.

PBYI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 210 of 231 cases where PBYI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. PBYI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 44 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 54 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.640) is normal, around the industry mean (2.788). P/E Ratio (18.434) is within average values for comparable stocks, (-0.376). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.911) among similar stocks. P/S Ratio (2.105) is also within normal values, averaging (440.869).

A.I.Advisor
a Summary for RYTM with price predictions
Nov 05, 2026

Momentum Indicator for RYTM turns positive, indicating new upward trend

RYTM saw its Momentum Indicator move above the 0 level on November 04, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 75 similar instances where the indicator turned positive. In 62 of the 75 cases, the stock moved higher in the following days. The odds of a move higher are at 83%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for RYTM just turned positive on October 20, 2026. Looking at past instances where RYTM's MACD turned positive, the stock continued to rise in 35 of 50 cases over the following month. The odds of a continued upward trend are 70%.

RYTM moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +3.26% 3-day Advance, the price is estimated to grow further. Considering data from situations where RYTM advanced for three days, in 236 of 295 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

Bearish Trend Analysis

The 10-day RSI Indicator for RYTM moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 21 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 70%.

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

The 50-day moving average for RYTM moved below the 200-day moving average on November 02, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RYTM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 73%.

RYTM broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for RYTM entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 14 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. RYTM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 47 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: RYTM's P/B Ratio (70.214) is slightly higher than the industry average of (2.788). P/E Ratio (-33.660) is within average values for comparable stocks, (-0.376). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.911) among similar stocks. P/S Ratio (27.548) is also within normal values, averaging (440.869).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

FUNDAMENTALS RATINGS
PBYI vs RYTM: Fundamental Ratings
PBYI
RYTM
OUTLOOK RATING
1..100
8512
VALUATION
overvalued / fair valued / undervalued
1..100
85
Overvalued
93
Overvalued
PROFIT vs RISK RATING
1..100
5414
SMR RATING
1..100
44100
PRICE GROWTH RATING
1..100
3542
P/E GROWTH RATING
1..100
247
SEASONALITY SCORE
1..100
3150

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PBYI's Valuation (85) in the Biotechnology industry is in the same range as RYTM (93). This means that PBYI’s stock grew similarly to RYTM’s over the last 12 months.

RYTM's Profit vs Risk Rating (14) in the Biotechnology industry is somewhat better than the same rating for PBYI (54). This means that RYTM’s stock grew somewhat faster than PBYI’s over the last 12 months.

PBYI's SMR Rating (44) in the Biotechnology industry is somewhat better than the same rating for RYTM (100). This means that PBYI’s stock grew somewhat faster than RYTM’s over the last 12 months.

PBYI's Price Growth Rating (35) in the Biotechnology industry is in the same range as RYTM (42). This means that PBYI’s stock grew similarly to RYTM’s over the last 12 months.

PBYI's P/E Growth Rating (2) in the Biotechnology industry is somewhat better than the same rating for RYTM (47). This means that PBYI’s stock grew somewhat faster than RYTM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PBYIRYTM
RSI
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
70%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
85%
Momentum
ODDS (%)
Bearish Trend 1 day ago
78%
Bullish Trend 1 day ago
83%
MACD
ODDS (%)
Bearish Trend 1 day ago
77%
Bullish Trend 1 day ago
70%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
79%
Bullish Trend 1 day ago
81%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
75%
Advances
ODDS (%)
Bullish Trend 3 days ago
89%
Bullish Trend 11 days ago
80%
Declines
ODDS (%)
Bearish Trend 5 days ago
79%
Bearish Trend 25 days ago
73%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 1 day ago
81%
Aroon
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
84%
COMPARISON
Comparison
Nov 06, 2026
Stock price -- (PBYI: $9.77 vs. RYTM: $105.02)
Brand notoriety: PBYI and RYTM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PBYI: 156% vs. RYTM: 565%
Market capitalization -- PBYI: $504.33M vs. RYTM: $7.23B
PBYI [@Biotechnology] is valued at $504.33M. RYTM’s [@Biotechnology] market capitalization is $7.23B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $137.5B. The average market capitalization across the [@Biotechnology] industry is $2.16B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PBYI’s FA Score shows that 1 FA rating(s) are green while RYTM’s FA Score has 1 green FA rating(s).

  • PBYI’s FA Score: 1 green, 4 red.
  • RYTM’s FA Score: 1 green, 4 red.
According to our system of comparison, PBYI is a better buy in the long-term than RYTM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PBYI’s TA Score shows that 4 TA indicator(s) are bullish while RYTM’s TA Score has 4 bullish TA indicator(s).

  • PBYI’s TA Score: 4 bullish, 5 bearish.
  • RYTM’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, PBYI is a better buy in the short-term than RYTM.

Price Growth

PBYI (@Biotechnology) experienced а -7.31% price change this week, while RYTM (@Biotechnology) price change was +12.84% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.71%. For the same industry, the average monthly price growth was -6.49%, and the average quarterly price growth was -17.15%.

Reported Earning Dates

PBYI is expected to report earnings on Mar 04, 2027.

RYTM is expected to report earnings on Mar 03, 2027.

Industries' Descriptions

@Biotechnology (+4.71% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
TSEC25.180.05
+0.20%
Touchstone Securitized Income ETF (TSEC)
OILT30.73-0.69
-2.21%
Texas Capital Texas Oil Index ETF (OILT)
QVAL63.35-1.79
-2.75%
Alpha Architect US Quantitative Value ETF (QVAL)
VDE171.07-5.35
-3.03%
Vanguard Energy ETF (VDE)
RDTL3.74-0.70
-15.77%
GraniteShares 2x Long RDDT Daily ETF (RDTL)